The Onsemble 2013 Fall Conference — which is co-hosted by the Yale Center for Clinical Investigation and will take place September 18-20 in New Haven, Conn. — will host more than 200 clinical research professionals from leading research institutions. It offers a great opportunity to network and collaborate on key issues in the industry. Here are the top 3 reasons you can’t miss the upcoming conference.
No. 1: Conference Agenda Includes Hot Topics of Interest
Want to learn more about risk-based monitoring, 21 CFR Part 11, or how leading institutions are measuring and improving upon clinical research operations? The Onsemble conference will feature discussion on all these topics and more. Separate sessions will also focus on how institutions are using functionality within the OnCore® Enterprise Research system — such as the Electronic Protocol Review and Monitoring System and the Data Safety and Monitoring Committee management functionality — to support their operations.
No. 2: Hear from Experts in the Field
The conference offers a unique opportunity to hear from leading experts in clinical research. Among the special guest presentations is a keynote address that will be delivered by Dr. Thomas Lynch, the director of the Yale Cancer Center. Dr. Lynch is an expert in the treatment of lung cancer with a special interest in personalized medicine. He is internationally known for his leadership in the development of novel therapies for the treatment of lung cancer. Using the molecular profile of lung tumors, he and his research team have developed methods to predict a tumor’s response to targeted drugs based on mutations in a certain gene. The resulting information enables oncologists to create treatment plans that more effectively target each patient’s specific tumor type. This kind of customized care, often referred to as personalized medicine, is a standard of practice at Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven. During his keynote presentation, he will discuss research at the Yale Cancer Center and the future direction of operations.
A second keynote presentation will be delivered by Mark Barnes, partner at the firm Ropes & Gray, LLP. Barnes focuses his practice in the areas of research, advising clients throughout higher education and the health care industry, including pharmaceutical companies, medical device manufacturers, hospitals, and universities. He has extensive experience in legal issues related to research with humans and animals, stem cell and genetic research, research grants and contracts, research misconduct, and international research. Barnes also frequently advises clients on clinical trials compliance, Medicare reimbursement, False Claims Act issues, and medical privacy. His presentation will focus on the regulatory environment in clinical research, discussing challenges and helpful strategies for institutions.
No. 3: Network with Clinical Research Professionals
The Onsemble conference offers great ways connect with your peers in clinical research. There are numerous networking sessions scheduled as part of the fall event. A pre-conference reception will be held at the Omni New Haven Hotel at Yale where attendees can mingle with peers before the opening day of the General Session. The Yale Center for Clinical Investigation will also host a Welcome Reception on campus after the conclusion of the first day of the General Session. Forte will host a networking dinner at the conclusion of the second day of the General Session. Don’t miss out on the many great opportunities to network!
Share your experience
Have you attended the Onsemble conferences? What do you consider the “can’t miss” events? Share your experience with others by leaving a comment below.
About the Onsemble Conferences
The semi-annual Onsemble conferences are open to all clinical research professionals at academic research institutions and are facilitated by Forte Research Systems. The majority of attendees are members of the Onsemble community, which is largely comprised of OnCore users. With the vision of “for the members, by the members,” the majority of content is generated and presented by the members of the community. The community is comprised of CTSAs, cancer centers, children’s hospitals, research consortia, and academic medical centers.
Those who attend are largely members of Clinical Trials Office leadership, clinical research associates, data managers, and regulatory managers. Other attendees represent study financials management, clinical informatics, and biostatistics teams.